SCHEMBL5151740

SCHEMBL5151740

CC(C)(C)OC(=O)NCCc1cnn(CCOC(c2ccccc2)(c2ccccc2)c2ccccc2)c1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.39
IDO1 P14902 3/20 0.39
SIGMAR1 Q99720 3/20 0.38
SCN9A Q15858 1/20 0.37
NAMPT P43490 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GFER P55789 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
DRD2 P14416 2/20 0.36
BCHE P06276 1/20 0.35
KIF11 P52732 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147591 0.83 SIGMAR1 (0.39) IDO1SIGMAR1SCN9ANAMPTCKS1B
SCHEMBL5148509 0.79 KDM4A (0.34) IDO1SIGMAR1SCN9ANAMPTCKS1B
SCHEMBL5151844 0.77 KIF11 (0.54) TSHRKIF11
SCHEMBL27603550 0.76 SIGMAR1 (0.38) IDO1SIGMAR1DRD2CA12CA1
SCHEMBL5148562 0.76 KIF11 (0.51) TSHRKIF11
SCHEMBL5148643 0.75 KIF11 (0.51) TSHRKIF11
SCHEMBL5147565 0.74 KIF11 (0.40) ALDH1A1KIF11
SCHEMBL5685924 0.74 NQO2 (0.37) NQO2IDO1SIGMAR1SCN9ANAMPT
SCHEMBL6065295 0.72 IDO1 (0.33) IDO1SIGMAR1SCN9ANAMPTCKS1B
SCHEMBL5148644 0.71 KDM4E (0.41) NAMPTALDH1A1GFERLMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179801-B2 Cephem compounds ASTELLAS PHARMA INC. (JP) 2007-02-20 US disclosed
EP-1392704-B1 CEPHEM COMPOUNDS ASTELLAS PHARMA INC (JP) 2006-02-22 EP disclosed
US-20040248875-A1 Cephem compounds ASTELLAS PHARMA INC. (JP) 2004-12-09 US disclosed
CN-1522259-A Cephem compounds ����ҩƷ��ҵ��ʽ���� 2004-08-18 CN disclosed
EP-1392704-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-03 EP disclosed
WO-2002090364-A1 CEPHEM COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248875-A1 Cephem compounds CEP170, C1S, SLC7A1 NQO2 754/4885IDO1 1914/4885SIGMAR1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.